Vivox

What Vivox does

Vivox is a privately-held preclinical Contract Research Organization (CRO) founded in 2018 and headquartered in Yokneam Ilit, Israel. The company delivers in vivo and in vitro research services, histopathology, GLP-compliant studies, and specialized disease models to pharmaceutical, biotechnology, medical device, and academic clients, primarily in Israel. Its service portfolio spans immunological, metabolic, neurological, renal, oncological, and general pharmacology models, supported by special surgical expertise including microinjection and cannulation techniques. Vivox also operates the Vivox Hub, a 1,500+ square meter shared laboratory and office facility in Yokneam Ilit serving biotech startups.

The company's core technical capabilities rest on an IVIS optical imaging system for non-invasive tumor and biodistribution monitoring, advanced histopathology services including IHC, immunofluorescence, and RNA FISH staining, and flow cytometry (FACS) analysis delivered through a partnership with Almog Diagnostics. Pathological consultation is anchored by Professor Avraham Nyska, a world-renowned toxicological pathologist (DVM, Dipl. ECVP, IATP Fellow). Vivox holds GLP certification and a cannabis-research license, enabling regulatory-grade preclinical studies including cannabis-based therapy work that few Israeli CROs offer. The team of approximately 20+ includes multiple Ph.D. scientists, study directors, lab technicians, and surgical specialists.

Vivox operates a B2B professional services model, with quote-based, custom-built studies priced per project scope and delivered through direct enterprise sales. Pricing is not publicly disclosed, no revenue figures are available, no funding rounds have been disclosed, and the company remains founder-controlled (co-founded by CEO Ely Elbaz and Omer Miller). Distribution is single-country (Israel) via direct engagement. Strategic priorities inferred from product and infrastructure investment include scaling the Hub ecosystem, broadening therapeutic-area coverage, and leveraging regulatory credentials as differentiation versus larger international CRO competitors.

Name

Vivox

Legal name

Vivox Ltd.

Website

https://vivox.co.il

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Vivox is an Israeli preclinical Contract Research Organization founded in 2018 that provides in vivo and in vitro studies, histopathology, and GLP-compliant studies to pharmaceutical, biotechnology, and medical device clients primarily in Israel.

Ownership category

akta.pro rank

Product category

Contract Research Organization (Preclinical CRO Services)

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industries

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Clinical CROs (Phase I–IV) (HLAGAAAA), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Preclinical CRO services
• In vivo studies
• In vitro research
• GLP compliant studies
• Histology services

Headquarters

HQ city

Agudat Israel

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Preclinical CRO Services: Professional preclinical research services including in-vivo and in-vitro studies, GLP studies, histology, and special surgical expertise. Services are tailored to client needs with custom-made experiments, offering study design, execution, analysis, and reporting.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Vivox is a Contract Research Organization (CRO) that provides professional preclinical research services to pharmaceutical, biotechnology, and medical device companies. Its offerings span in-vivo rodent studies (across immunology, metabolic, neurological, renal, and oncological models), in-vitro expertise (cell viability, immunoassays, molecular biology, FACS), GLP-compliant studies, histology and histopathology services, and a shared laboratory coworking space (Vivox Hub) for biotech startups. Each engagement is custom-designed by Vivox scientists and delivered end-to-end from study design through execution, analysis, and reporting.

Product overview

Vivox is a Contract Research Organization (CRO) providing end-to-end preclinical research services to pharmaceutical, biotechnology, and medical device companies. The company operates as a single unified service offering rather than a modular platform, encompassing in vivo and in vitro studies, histology, GLP-compliant studies, and shared workspace facilities. The core portfolio consists of specialized preclinical models across therapeutic areas (immunology, metabolic diseases, neurology, renal diseases, oncology) combined with surgical expertise, analytical services, and a startup hub facility. Services are delivered through a team of expert scientists who conduct tailor-made experiments for each client.

Differentiator

Problem solved

Functional benefit

Products and services

• In Vivo Studies Preclinical in vivo research services using rodent models to study biological processes and disease mechanisms, supporting pharmaceutical and biotech companies in drug development across multiple therapeutic areas.
• In Vitro Expertise Advanced in vitro research services including cell viability assays, ex-vivo studies, immunoassays, protein analysis, molecular biology, and FACS analysis delivered via Almog Diagnostics partnership.
• Histology Service Tissue analysis and preparation services including routine histology, project-specific applications (RNA FISH, IHC, immunofluorescence), and pathological consultation in collaboration with Prof. Avraham Nyska.
• GLP Studies Good Laboratory Practice compliant studies ensuring reliability, accuracy, and quality of data for regulatory submissions in pharmaceutical development.
• General Models General in vivo models for pharmacokinetics (PK), pharmacodynamics (PD), toxicity studies, Maximum Tolerated Dose (MTD), and various disease models including wound healing and angiogenesis.
• Inflammatory and Immunological Models Preclinical models for studying immune responses including EAE/MS models (MOG and PLP-induced), DTH, IBD (DSS and TNBS-induced), CLP sepsis model, psoriasis, lupus (SLE), and arthritis (CIA) models.
• Metabolic Disease Models Metabolic research models including obesity (high-fat diet), DB/DB and NOD mice for diabetes, STZ-induced T1DM, glucose/insulin tolerance tests, and biomarker assessment.
• Neurological Disorder Models CNS research models including Parkinson's disease (6-OHDA, MPTP), anxiety/depression models, spinal cord injury, rotarod testing, memory tests (NORT, Y-maze, Morris water maze), and neurotoxin-induced Alzheimer's and epilepsy models.
• Acute Kidney Injury Models Renal disease models including unilateral ureteral obstruction (UUO), nephrectomy models (5/6 NX), ischemia/reperfusion-induced AKI, and chronic kidney disease models.
• Oncological Models Cancer research models including orthotopic tumor inoculation techniques, metastatic cancer models with IVIS imaging, cancer cell lines, primary cells, stem cells, and humanized mouse models.
• Special Surgical Expertise Advanced surgical procedures including microinjection techniques (intranasal, intratracheal, intravitreal, intrathecal), cannulation procedures, catheter implantations, and specialized models like myocardial infarction induction.
• Vivox Hub Shared workspace and laboratory facility for biotech startups offering over 1,500 m2 of state-of-the-art space including private offices, meeting rooms, and fully equipped laboratories with FACS, PCR, ELISA reader, and other research equipment, with access to Vivox's preclinical knowledge and services.

Quantifiable outcome

• Successfully supports FDA IND applications
• +1 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Almog DiagnosticscoreTechnology or IntegrationVivox collaborates with Almog Diagnostics for high-level FACS (Fluorescence-Activated Cell Sorting) analysis. Almog provides flow cytometry services including antibody panel design, tissue dissociation, multi-color sample staining (up to 35 fluorochromes), samples acquisition on advanced Flow Cytometers, high throughput capabilities (up to 96 well plates), and detailed analysis reports.
• Professor Avraham NyskacoreStrategic or Co-development PartnerVivox collaborates with Professor Avraham Nyska, a world-renowned expert in toxicological pathology. Prof. Nyska holds DVM, Diplomate of the European College of Veterinary Pathology (Dipl. ECVP), and Fellow of the International Academy of Toxicologic Pathology (IATP). His extensive expertise in laboratory animal pathology supports Vivox's pathological evaluation and data analysis.
• Vivox Hub StartupsminorStrategic or Co-development PartnerVivox Hub offers selected biotech startups infrastructure including workspace (over 1500 m2), private offices, meeting rooms, and fully equipped laboratories with access to Vivox's preclinical knowledge and services.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Charles River Laboratories: Global preclinical CRO leader offering in-vivo and in-vitro services across therapeutic areas for pharma and biotech. Comparable to Vivox in core preclinical offerings but vastly larger in scale, geographic reach, and service breadth.
• WuXi AppTec: China-based global CRO/CDMO providing preclinical discovery, in-vivo pharmacology and toxicology services. Directly comparable in preclinical CRO scope to Vivox but at much greater scale.
• Eurofins Discovery Services: Global CRO offering in-vivo pharmacology, safety assessment, and bioanalytical services. Overlaps significantly with Vivox's preclinical GLP-capable service portfolio.
• Pharmaron: Integrated CRO/CDMO with preclinical in-vivo and in-vitro capabilities across therapeutic areas. Similar preclinical CRO focus to Vivox with broader global operations.
• Labcorp Drug Development (Fortrea): Large-scale clinical and preclinical CRO offering the full drug development continuum. Overlaps with Vivox in preclinical research and laboratory services, with substantially broader global footprint.

Direct peers

• Inotiv: US-based preclinical CRO specializing in animal model research, toxicology, and discovery services. Directly comparable to Vivox in preclinical CRO focus and therapeutic model coverage.
• Evotec (SE): Integrated drug discovery and preclinical CRO offering in-vivo and in-vitro research for biotech and pharma. Direct preclinical CRO peer to Vivox with similar operating model.
• Sygnature Discovery: UK-based preclinical CRO offering in-vivo pharmacology and disease model services. Comparable to Vivox as a focused preclinical CRO serving biotech and pharma.
• Envigo (now Inotiv): Preclinical CRO providing research models and preclinical research services. Overlaps with Vivox in offering rodent-based in-vivo studies for drug development.

Others

• Almog Diagnostics: Israeli flow cytometry and diagnostics provider that is also a documented Vivox partner for FACS analysis. Comparable as an adjacent Israeli life sciences services provider in the same ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/vivox-experts-in-vivo

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vivox